title: Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.
abstract: Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer.
authors: Department of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, 6720, Hungary.
authors: Renáta
authors: R
authors: Kószó
authors: Department of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, 6720, Hungary.
authors: Dóra
authors: D
authors: Sántha
authors: Borsod-Abauj-Zemplén County Hospital, Szentpéteri kapu 72-76, Miskolc, 3526, Hungary.
authors: László
authors: L
authors: Büdi
authors: Szabolcs-Szatmár-Bereg County Jósa András Hospital, Szent István u. 68, Nyíregyháza, 4400, Hungary.
authors: József
authors: J
authors: Erfán
authors: Kaposi Mór Teaching Hospital, Tallián Gy. u. 20-32, Kaposvár, 7400, Hungary.
authors: Károly
authors: K
authors: Győrfy
authors: Medical Center, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.
authors: Zsolt
authors: Z
authors: Horváth
authors: 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, Budapest, 1125, Hungary.
authors: Judit
authors: J
authors: Kocsis
authors: Uzsoki Hospital, Uzsoki u. 29-41, Budapest, 1145, Hungary.
authors: László
authors: L
authors: Landherr
authors: National Institute of Oncology, Ráth György u. 7-9, Budapest, 1126, Hungary.
authors: Erika
authors: E
authors: Hitre
authors: Zala County Hospital, Zrínyi M. u. 1, Zalaegerszeg, 8900, Hungary.
authors: Károly
authors: K
authors: Máhr
authors: Bács-Kiskun County Hospital, Nyíri u. 38, Kecskemét, 6000, Hungary.
authors: Gábor
authors: G
authors: Pajkos
authors: Hungarian Army Medical Center, Róbert Károly körút 44, Budapest, 1134, Hungary.
authors: Zsuzsanna
authors: Z
authors: Pápai
authors: Department of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, 6720, Hungary. kahan.zsuzsanna@med.u-szeged.hu.
authors: Zsuzsanna
authors: Z
authors: Kahán
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000069287:Capecitabine / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D006814:Hungary; D008875:Middle Aged; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000069287:Capecitabine; D000077143:Docetaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids
keywords: Capecitabine; Docetaxel; HER2-negative metastatic breast cancer; Toxicity